SCHEMBL2143785

SCHEMBL2143785

O=C(O)c1cc(Br)c2cccnc2c1O

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 9/20 0.78
▸ TP53 P04637 6/20 0.66
▸ KMT2A Q03164 6/20 0.66
▸ HSP90AA1 P07900 6/20 0.66
▸ MEN1 O00255 5/20 0.66
▸ HTT P42858 4/20 0.66
▸ SMN1; SMN2 Q16637 4/20 0.66
▸ TDP1 Q9NUW8 3/20 0.66
▸ USP2 O75604 2/20 0.66
▸ ALDH1A1 P00352 5/20 0.58
▸ L3MBTL1 Q9Y468 5/20 0.54
▸ KDM4A O75164 2/20 0.54
▸ EGLN1 Q9GZT9 2/20 0.54
▸ KDM6B O15054 1/20 0.54
▸ KDM6A O15550 1/20 0.54
▸ TET3 O43151 1/20 0.54
▸ KDM4B O94953 1/20 0.54
▸ KDM5C P41229 1/20 0.54
▸ KDM4D Q6B0I6 1/20 0.54
▸ TET2 Q6N021 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28463407 0.85 KDM4E (0.74) KDM4ETP53KMT2AHSP90AA1MEN1
SCHEMBL13858129 0.83 KDM4E (0.62) KDM4ETP53KMT2AHSP90AA1MEN1
SCHEMBL19358745 0.83 KDM4E (0.62) KDM4ETP53KMT2AHSP90AA1MEN1
SCHEMBL21902359 0.82 KDM4E (0.59) KDM4ETP53KMT2AHSP90AA1MEN1
SCHEMBL7688612 0.81 KDM4E (0.60) KDM4ETP53KMT2AHSP90AA1MEN1
SCHEMBL4061248 0.81 KDM4E (0.66) KDM4ETP53KMT2AHSP90AA1MEN1
Broxyquinoline SCHEMBL30485535 0.80 KDM4E (1.00) KDM4ETP53KMT2AHSP90AA1MEN1
Broxyquinoline SCHEMBL29607319 0.80 KDM4E (1.00) KDM4ETP53KMT2AHSP90AA1MEN1
Broxyquinoline SCHEMBL115293 0.80 KDM4E (1.00) KDM4ETP53KMT2AHSP90AA1MEN1
SCHEMBL13255537 0.80 KDM4E (0.58) KDM4ETP53KMT2AHSP90AA1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2519505-B1 TERTIARY 8-HYDROXYQUINOLINE-7-CARBOXAMIDE DERIVATIVES AND USES THEREOF POLICHEM SA (LU) 2015-05-27 — — EP disclosed
EP-2519505-B1 TERTIARY 8-HYDROXYQUINOLINE-7-CARBOXAMIDE DERIVATIVES AND USES THEREOF POLICHEM SA (LU) 2015-05-27 — — EP disclosed
US-8729098-B2 Tertiary 8-hydroxyquinoline-7-carboxamide derivatives and uses thereof POLICHEM SA (LU) 2014-05-20 — — US disclosed
US-8729098-B2 Tertiary 8-hydroxyquinoline-7-carboxamide derivatives and uses thereof POLICHEM SA (LU) 2014-05-20 — — US disclosed
US-8729098-B2 Tertiary 8-hydroxyquinoline-7-carboxamide derivatives and uses thereof POLICHEM SA (LU) 2014-05-20 — — US disclosed
US-20120309751-A1 TERTIARY 8-HYDROXYQUINOLINE-7-CARBOXAMIDE DERIVATIVES AND USES THEREOF POLICHEM SA (LU) 2012-12-06 — — US disclosed
US-20120309751-A1 TERTIARY 8-HYDROXYQUINOLINE-7-CARBOXAMIDE DERIVATIVES AND USES THEREOF POLICHEM SA (LU) 2012-12-06 — — US disclosed
US-20120309751-A1 TERTIARY 8-HYDROXYQUINOLINE-7-CARBOXAMIDE DERIVATIVES AND USES THEREOF POLICHEM SA (LU) 2012-12-06 — — US disclosed
EP-2519505-A1 NEW TERTIARY 8-HYDROXYQUINOLINE-7-CARBOXAMIDE DERIVATIVES AND USES THEREOF Polichem SA (LU) 2012-11-07 — — EP disclosed
EP-2345643-A1 New tertiary 8-hydroxyquinoline-7-carboxamide derivatives and uses thereof POLICHEM S.A. (LU) 2011-07-20 — — EP disclosed
WO-2011080264-A1 NEW TERTIARY 8-HYDROXYQUINOLINE-7-CARBOXAMIDE DERIVATIVES AND USES THEREOF POLICHEM S.A. (LU) 2011-07-07 — — WO disclosed
WO-2011080264-A1 NEW TERTIARY 8-HYDROXYQUINOLINE-7-CARBOXAMIDE DERIVATIVES AND USES THEREOF POLICHEM S.A. (LU) 2011-07-07 — — WO disclosed
US-6500842-B1 N-((4-CHLOROPHENYL)METHYL)-8-HYDROXY-7-QUINOLINECARBOXAMIDE ADMINISTERED AS VIRICIDES AGAINST HERPES VIRUS PHARMACIA & UPJOHN COMPANY 2002-12-31 — — US disclosed
US-6310211-B1 ANTI-VIRAL ACTIVITY AGAINST HERPES VIRUS, CYTOMEGALOVIRUS. MANY OF THESE COMPOUNDS ARE ALSO ACTIVE AGAINST VARICELLA ZOSTER VIRUS, EPSTEIN-BARR VIRUS, HERPES SIMPLEX VIRUS AND HUMAN HERPES VIRUS TYPE 8 PHARMACIA & UPJOHN COMPANY 2001-10-30 — — US disclosed
US-6252080-B1 HERPES, CYTOMEGALO VIRUS PHARMACIA & UPJOHN COMPANY 2001-06-26 — — US disclosed
US-6211376-B1 HERPES VIRUS, CYTOMEGALO VIRUS, VARICELLA-ZOSTER VIRUS,EPSTEIN-BARR VIRUS PHARMACIA & UPJOHN COMPANY 2001-04-03 — — US disclosed
EP-0927164-A1 8-HYDROXY-7-SUBSTITUTED QUINOLINES AS ANTI-VIRAL AGENTS PHARMACIA & UPJOHN COMPANY (US) 1999-07-07 — — EP disclosed
WO-1998011073-A1 8-HYDROXY-7-SUBSTITUTED QUINOLINES AS ANTI-VIRAL AGENTS PHARMACIA & UPJOHN COMPANY (US) 1998-03-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120309751-A1 TERTIARY 8-HYDROXYQUINOLINE-7-CARBOXAMIDE DERIVATIVES AND USES THEREOF TUBA8, SUCLG1, TUBB8 KDM4E 2814/4885TP53 1727/4885KMT2A 1430/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback